What Is GLP-1? How It Works, Medications, Side Effects, and What You Should Know

Key Takeaways

GLP-1 is a naturally occurring incretin hormone produced by L-cells in the small intestine within minutes of eating. It works through three parallel mechanisms: stimulating glucose-dependent insulin secretion from pancreatic beta cells, suppressing glucagon release from alpha cells, and slowing gastric emptying to increase satiety.

A 2025 systematic review of spanning PubMed, Embase, and Cochrane found GLP-1 receptor agonists deliver HbA1c reductions of 1.5–2.0% in type 2 diabetes, 7–24% body weight loss in obesity treatment, and 14–20% reduction in major adverse cardiovascular events (Emerging Frontiers in GLP-1 Therapeutics, PMC 2025). Gastrointestinal side effects (nausea, vomiting, diarrhea) are the most common reason people discontinue treatment. A 2026 analysis of over 9,000 patients found that those who stopped semaglutide or tirzepatide regained an average of nearly 2 pounds per month (Oxford University, 2026).

GLP-1, short for glucagon-like peptide-1, is a hormone your body produces naturally. It belongs to a class of hormones called incretins, which are released by cells in your small intestine after you eat. In healthy digestion, GLP-1 tells the pancreas to release insulin (lowering blood sugar), tells the liver to stop dumping glucose into the bloodstream, slows the rate at which food leaves your stomach (so you feel full longer), and signals the brain's hypothalamus to reduce appetite. This is the normal machinery. It runs quietly in the background every time you eat.

What made GLP-1 a cultural phenomenon is not the hormone itself but the drugs that mimic it. Pharmaceutical GLP-1 receptor agonists , semaglutide (Ozempic, Wegovy), tirzepatide (Mounjaro, Zepbound), and others , bind to the same receptors but last far longer than natural GLP-1 (which your body breaks down within 2–3 minutes). The result is a sustained version of your body's own appetite and blood-sugar regulation, producing weight loss that was previously achievable only through bariatric surgery.

As of mid-2026, roughly 11% of American adults are using a GLP-1 medication for weight loss, up from 3% in 2024, and 91% are aware these drugs exist (Gallup National Health and Well-Being Index, July 2026). This guide covers how GLP-1 works, the medications available, their side effects, who they are and are not for, and the nutritional considerations that come with using them.

A quick disclosure: YourHealthier sells a GLP-1 Companion supplement formulated to support nutritional needs during GLP-1 therapy. This guide is not a sales pitch for that product; it is an objective overview of GLP-1 biology, the prescription medications, and the evidence behind them.

🩺 Doctor's Clinical Note

Dr. Jill Palko, MD, FACOG Cleveland Clinic-Trained · Board-Certified OB/GYN NPI #1093033011 · View Credentials

"GLP-1 medications are longer-acting forms of the hormone your body naturally produces, which signals your brain that you are full after you eat. This helps regulate blood sugar levels and promote weight loss. There are many different GLP-1 medications available that have been proven highly effective. Please check with your trusted medical provider to see if these medications are right for you."

How does GLP-1 work in the body?

Your body's GLP-1 system operates on a simple feedback loop: you eat, L-cells in your intestinal lining detect nutrients (especially glucose and fats), and they secrete GLP-1 into the bloodstream. From there, GLP-1 acts on three targets simultaneously.

Pancreas. GLP-1 binds to receptors on beta cells and stimulates insulin secretion, but only when blood glucose is elevated. This glucose-dependent mechanism is why GLP-1 drugs carry a lower risk of hypoglycemia than older diabetes medications like sulfonylureas, which stimulate insulin regardless of blood sugar levels. GLP-1 also suppresses glucagon secretion from alpha cells, reducing the liver's glucose output.

Stomach. GLP-1 slows gastric emptying, the rate at which food moves from the stomach into the small intestine. This is the mechanism behind the prolonged fullness that GLP-1 drug users describe. It is also the mechanism behind the most common side effect: nausea. The stomach is holding food longer than the brain expects.

Brain. GLP-1 receptors exist in the hypothalamus and brainstem areas that regulate appetite and reward. Activation of these receptors reduces hunger signals and, according to emerging research, may dampen the hedonic (pleasure-driven) aspects of eating, which is why some users report reduced cravings not just for food but for alcohol and nicotine as well.

The critical limitation of natural GLP-1 is its half-life: roughly 2–3 minutes. An enzyme called DPP-4 (dipeptidyl peptidase-4) rapidly degrades it. This is why the hormone works as a meal-by-meal signal rather than a sustained force. GLP-1 receptor agonist drugs solve this by modifying the molecule's structure to resist DPP-4 degradation, extending the half-life from minutes to days (for injectable semaglutide, approximately 7 days), which is why they are dosed weekly rather than with every meal.

How does Ozempic (semaglutide) work?

Ozempic mimics GLP-1, binding to receptors in the brain and gut to reduce appetite, slow gastric emptying, and stimulate insulin release. The active ingredient, semaglutide, is a modified GLP-1 peptide engineered to resist enzymatic breakdown and last roughly 7 days per injection, compared to the 2-minute half-life of natural GLP-1.

Is Ozempic insulin?

No. Ozempic is a GLP-1 receptor agonist, not insulin. It stimulates your pancreas to release insulin only when blood sugar is elevated, which is why it carries a lower risk of hypoglycemia than injectable insulin. People on insulin and Ozempic simultaneously need dose adjustments supervised by their prescriber.

What are the types of GLP-1 medications?

GLP-1 receptor agonists have evolved through three generations, each with improved efficacy and convenience. All are prescription medications. None are available over the counter.

What are GLP-1 injections (shots)?

GLP-1 injections, also called weight loss shots or GLP-1 shots, are the most common form of GLP-1 medication. All but two GLP-1 drugs are injectable: Ozempic, Wegovy, Mounjaro, Zepbound, Saxenda, Victoza, Trulicity, Byetta, and Bydureon are all subcutaneous injections. Only Rybelsus and Foundayo are pills.

The injection is delivered with a prefilled pen into the fat layer under the skin, abdomen, thigh, or upper arm, and rotated between sites. Most are weekly; a few older agents are daily or twice-daily. The needle is short and fine (typically 29–32 gauge), and most people describe the injection as close to painless.

First generation: short-acting

Exenatide (Byetta) was the first GLP-1 receptor agonist approved by the FDA in 2005. It requires twice-daily injection and produces modest weight loss (2–4% of body weight; FDA prescribing information). A longer-acting version, Bydureon, moved to once-weekly dosing. These are now rarely prescribed for weight management given the availability of more effective options, but remain in use for type 2 diabetes.

Second generation: long-acting

Liraglutide is available as Victoza (for type 2 diabetes) and Saxenda (for weight management, FDA-approved 2014). It requires daily injection and produces approximately 5–8% body weight loss (FDA prescribing information). Dulaglutide (Trulicity) is a once-weekly injection approved for type 2 diabetes with demonstrated cardiovascular benefits.

Semaglutide represents the major clinical leap. It is available in three formulations: Ozempic , once-weekly injection, FDA-approved for type 2 diabetes (2017), widely prescribed off-label for weight loss before Wegovy's approval. Wegovy , once-weekly injection at a higher dose, FDA-approved specifically for chronic weight management (2021), clinical trials (STEP program) demonstrated approximately 15% body weight loss over 68 weeks. Rybelsus , oral tablet taken daily, FDA-approved for type 2 diabetes (2019), an oral formulation of Wegovy for weight management received FDA approval in early 2026. (STEP 1, NEJM).

Third generation: multi-receptor agonists

Tirzepatide targets both GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors simultaneously, producing greater metabolic effects than GLP-1 alone: Mounjaro , once-weekly injection for type 2 diabetes (FDA-approved 2022). Zepbound , once-weekly injection for chronic weight management (FDA-approved 2023), clinical trials (SURMOUNT program) demonstrated up to 22.5% body weight loss, the highest of any approved anti-obesity medication. (SURMOUNT program).

Emerging candidates in late-stage development include CagriSema (semaglutide combined with cagrilintide, an amylin analog), retatrutide (a triple agonist targeting GLP-1, GIP, and glucagon receptors), and orforglipron (a non-peptide oral GLP-1 agonist that does not require the fasting restrictions of Rybelsus).

GLP-1 medication comparison (2026 FDA-approved drugs)

Medication	Active Ingredient	Route	Frequency	Approved For	Avg. Weight Loss
Ozempic	Semaglutide	Injection	Weekly	Type 2 diabetes	~10–14%
Wegovy	Semaglutide	Injection	Weekly	Weight management	~15%
Rybelsus	Semaglutide	Oral tablet	Daily	Type 2 diabetes	~5–8%
Mounjaro	Tirzepatide	Injection	Weekly	Type 2 diabetes	~15–20%
Zepbound	Tirzepatide	Injection	Weekly	Weight management	~20–22.5%
Saxenda	Liraglutide	Injection	Daily	Weight management	~5–8%

Efficacy figures reflect mean weight loss from landmark trials (STEP program for semaglutide, SURMOUNT program for tirzepatide) and FDA prescribing information. Individual results vary by dose, duration, diabetes status, and adherence.

What is Ozempic used for?

Ozempic (semaglutide 0.25–1.0 mg) is FDA-approved for type 2 diabetes. Wegovy is the same molecule at a higher dose (2.4 mg) approved for chronic weight management in adults with BMI 30+ or BMI 27+ with a weight-related condition. Ozempic is frequently prescribed off-label for weight loss, though insurance coverage for off-label use varies.

What is a GLP-1 receptor agonist?

A GLP-1 receptor agonist is a medication that mimics the natural hormone glucagon-like peptide-1 (GLP-1). Your gut releases GLP-1 after meals to signal fullness, slow gastric emptying, and stimulate insulin release. GLP-1 receptor agonists bind to the same receptors but at much higher and longer-lasting concentrations than your body produces naturally.

The term covers all medications in this class: semaglutide (Ozempic, Wegovy, Rybelsus), tirzepatide (Mounjaro, Zepbound, which is technically a dual GLP-1/GIP agonist), liraglutide (Saxenda, Victoza), dulaglutide (Trulicity), and exenatide (Byetta, Bydureon). Newer agents like orforglipron and survodutide are in late-stage trials. See the complete list below.

What does GLP-1 stand for?

GLP-1 stands for glucagon-like peptide-1, a 30-amino-acid hormone secreted by L-cells in the small intestine after meals. The name reflects its structural similarity to glucagon, though its metabolic effects are largely opposite: GLP-1 lowers blood sugar by stimulating insulin release, while glucagon raises it.

Is GLP-1 a peptide?

Yes. GLP-1 is a peptide hormone, and semaglutide (Ozempic, Wegovy) is a synthetic analog of that peptide with a C-18 fatty acid side chain attached. The fatty acid binds to albumin in the blood, extending its half-life from minutes to approximately 7 days, which is what makes once-weekly dosing possible.

What is Ozempic made of?

Semaglutide, a modified version of human GLP-1. Specifically, it is a 31-amino-acid peptide with two key modifications: an amino acid substitution at position 8 that resists DPP-4 enzyme degradation, and a C-18 fatty diacid chain at position 26 that binds albumin for sustained circulation.

Complete list of GLP-1 drugs available in 2026

Eleven GLP-1 receptor agonists are FDA-approved in the United States as of 2026, split across type 2 diabetes indications, chronic weight management indications, and in several cases both. Semaglutide and tirzepatide account for the overwhelming majority of prescriptions. All eleven require a prescription; none are available over the counter in any form.

Two things this list makes obvious. First, several molecules appear under multiple brand names at different doses for different indications, which is why patients are frequently confused about whether Ozempic and Wegovy are "the same drug." They contain the same active molecule at different maximum doses with different approved uses.

Second, the older agents are still approved but rarely chosen for weight management. Byetta and Bydureon produce 2 to 4% body weight loss compared with roughly 15% for semaglutide (STEP 1) and up to 22.5% for tirzepatide (SURMOUNT-1). They remain on formularies mostly for diabetes management and cost reasons.

Anything not on this list that is being sold as a GLP-1 is either a compounded preparation, which is not an FDA-approved finished drug, or a dietary supplement, which is not a GLP-1 receptor agonist at all.

→ What each of these costs with and without insurance
→ Head-to-head weight loss data across the major agents

When did Ozempic come out?

Ozempic (semaglutide for type 2 diabetes) received FDA approval in December 2017. Wegovy (semaglutide for weight management) followed in June 2021. The first GLP-1 receptor agonist, exenatide (Byetta), was approved in 2005, and tirzepatide (Mounjaro/Zepbound) arrived in 2022.

How long have GLP-1 medications been around?

Over 20 years. Exenatide (Byetta), the first GLP-1 receptor agonist, was FDA-approved in April 2005. The class has expanded to include liraglutide (2010), dulaglutide (2014), semaglutide (2017), and tirzepatide (2022). Long-term safety data now spans two decades of clinical use across millions of patients.

GLP-1 pills: are there oral GLP-1 drugs in 2026?

GLP-1 pills are oral versions of GLP-1 medications. Three oral GLP-1 options exist in 2026: Rybelsus (oral semaglutide, approved 2019 for type 2 diabetes), an oral semaglutide formulation for weight management approved in early 2026, and Foundayo (orforglipron), Eli Lilly's small-molecule agent approved April 1, 2026 for chronic weight management at $149 per month through LillyDirect. Orforglipron is the structurally different one, and that difference is why it is cheaper.

Semaglutide is a peptide. Peptides are destroyed by stomach acid and digestive enzymes, which is why oral semaglutide requires an absorption enhancer (SNAC) and strict dosing conditions per its FDA prescribing information: empty stomach, small sip of water, wait 30 minutes before eating or taking anything else. Absorption is variable even when the instructions are followed exactly.

Orforglipron is a small molecule, not a peptide. It survives the digestive tract without an absorption enhancer, can be taken with or without food, and costs substantially less to manufacture at scale. That combination is what makes it the first oral GLP-1 that competes on price rather than convenience alone.

GLP-1 pills vs injections: how do they compare?

The practical trade-off: injectables are more forgiving to take and generally more potent, while orals remove the needle and, in orforglipron's case, dramatically reduce cost. Adherence data on daily oral dosing versus weekly injection is still accumulating, and daily regimens historically show lower long-term adherence than weekly ones across drug classes.

One thing that does not change between formulations: the nutritional consequences. Reduced appetite means reduced intake regardless of how the drug enters the body, and the protein and micronutrient gaps that follow are identical.

→ Oral versus injectable cost breakdown
→ Covering the nutrient gaps either way

What side effects should you expect on GLP-1?

Gastrointestinal symptoms are the most frequent: nausea affects 22.8% of users, diarrhea 13%, and vomiting 9.1%, based on a 2026 meta-analysis of GLP-1 gastrointestinal adverse events. These are dose-dependent and typically fade within 4 to 8 weeks at each dose level.

For the complete breakdown by body system, frequency data, management strategies, and long-term risks, see our full guide: GLP-1 Side Effects: What to Expect and How to Manage.

Who is GLP-1 medication for (and who is it not for)?

GLP-1 receptor agonists are FDA-approved for two primary indications: type 2 diabetes (Ozempic, Mounjaro, Victoza, Trulicity, Rybelsus) to improve glycemic control, and chronic weight management (Wegovy, Zepbound) for adults with a BMI of 30+ or BMI 27+ with at least one weight-related comorbidity, alongside a reduced-calorie diet and increased physical activity.

Who should not use GLP-1 medications: individuals with a personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2); people with a history of pancreatitis (use with caution under supervision); pregnant or breastfeeding individuals (discontinue at least 2 months before planned pregnancy); individuals with severe gastroparesis or other GI motility disorders.

GLP-1 medications are prescription drugs requiring medical evaluation, ongoing monitoring, and dose titration by a licensed healthcare provider. They are not supplements, not available over the counter, and not appropriate for people who simply want to lose a few pounds without a clinical indication.

Can you take GLP-1 drugs if you are already thin?

Not through an FDA-approved indication. Weight-management approval requires a BMI of 30 or above, or 27 or above with at least one weight-related condition such as hypertension, type 2 diabetes, or sleep apnea. Below those thresholds, a GLP-1 prescription for weight loss is off-label, and the risk-benefit calculation shifts substantially against it.

The question comes up constantly, and it comes from two very different places. Some people at a normal BMI have genuine metabolic dysfunction: prediabetes, PCOS, insulin resistance with visceral adiposity that a BMI reading misses entirely. That is a legitimate clinical conversation with real evidence behind it. Others are at a healthy weight and want to be thinner, which is where the risks concentrate.

What actually goes wrong at low body weight on a GLP-1:

• Lean mass loss becomes disproportionate. With less fat mass to draw from, a larger share of weight lost comes from muscle. Pooled trial data puts lean mass at roughly 25% of total weight lost on average (network meta-analysis, 22 RCTs), and individual trial substudies have reported figures approaching 45% (Neeland, 2024).
• Nutritional deficits arrive faster. Someone eating 1,400 calories from a starting point of 1,800 has far less room than someone dropping from 3,000.
• Bone density is affected by rapid loss. The effect is measurable in trials and matters more in people who have less to lose.
• Disordered eating risk. Clinicians have raised concerns about GLP-1 use in people with a history of restriction or body dysmorphia, where pharmacological appetite suppression can reinforce an existing pattern.

There is a separate and expanding category worth distinguishing: GLP-1 medications prescribed for reasons other than weight, in people who are not overweight. Cardiovascular risk reduction, sleep apnea, and chronic kidney disease all have accumulating evidence, and some of those indications are not BMI-gated in the same way. That is not the same as prescribing for cosmetic weight loss at a normal BMI.

If you are at a healthy weight and considering a GLP-1, the more productive question for a clinician is what specific metabolic marker you are trying to move, and whether it can be moved without a drug that will also reduce your muscle mass.

→ What the weight loss data actually shows by starting BMI
→ Protecting lean mass during any GLP-1 course

How much weight do people regain after stopping GLP-1?

Weight regain is the norm, not the exception. A large 2026 analysis of over 9,000 patients found that people who stopped semaglutide or tirzepatide regained an average of nearly 2 pounds per month. The STEP 1 trial extension, which followed patients for a year after stopping semaglutide, showed participants had regained two-thirds of their lost weight by the end of that year (Stanford Medicine, 2026).

This is not a failure of willpower. It reflects the biology: obesity is a chronic condition involving reset appetite set points, altered hormonal signaling, and metabolic adaptation. When the exogenous GLP-1 signal is removed, the underlying drivers of weight gain return. This is why most obesity medicine specialists frame GLP-1 medications as long-term or indefinite treatments (similar to blood pressure or cholesterol medications), not short courses.

For those who do discontinue, maintaining weight loss requires aggressive lifestyle strategies: high protein intake (1.0–1.6 g per kg of body weight daily), consistent resistance training, and ongoing monitoring. For the full trial picture on how much weight each GLP-1 produces and how fast, see our dedicated guide.

Do natural GLP-1 foods exist?

Your body produces GLP-1 naturally in response to eating, and certain foods and nutrients appear to stimulate GLP-1 release more than others. The catch is that the magnitude of this natural stimulation is vastly smaller than what pharmaceutical GLP-1 agonists achieve, so "natural GLP-1 foods" should be understood as part of a healthy diet rather than an alternative to medication for anyone with a clinical indication. For the full evidence on each food, supplement, and how they compare to medication, see natural GLP-1: foods and compounds that support GLP-1.

Foods and nutrients associated with increased GLP-1 secretion include high-protein foods (eggs, Greek yogurt, lean meats, legumes), fiber-rich foods (oats, barley, vegetables, legumes) where soluble fiber is fermented by gut bacteria into short-chain fatty acids that stimulate L-cell GLP-1 secretion, healthy fats (avocado, olive oil, nuts), and fermented foods (yogurt, kefir, sauerkraut).

Berberine, a plant compound found in goldenseal and barberry, has been studied for its effects on glucose metabolism and has shown some evidence of increasing GLP-1 secretion in animal and small human studies. For a deeper look at this compound: berberine benefits and blood sugar support.

The honest synthesis: eating more protein, fiber, and healthy fats while reducing processed food and added sugar will support your body's natural GLP-1 production. It will not replicate the clinical effect of injectable semaglutide at 2.4 mg weekly. These are complementary strategies, not competing ones.

What nutritional gaps does GLP-1 medication create?

Reduced food intake on GLP-1 therapy creates predictable nutritional shortfalls that deserve attention. When you eat significantly less, you consume fewer micronutrients by default, even if your food choices are excellent. Hair loss is one of the most visible consequences of these gaps; see GLP-1 and hair loss: causes, prevention, and what helps.

Vitamin B12. GLP-1 receptor agonists slow gastric emptying and may reduce intrinsic factor availability, both of which impair B12 absorption. B12 deficiency can cause fatigue, cognitive fog, and peripheral neuropathy. Supplementation with methylcobalamin (the active form of B12) is a straightforward hedge.

Iron. Reduced food intake plus potential GI side effects can deplete iron stores, especially in menstruating women. Symptoms include fatigue, pallor, and exercise intolerance.

Zinc and magnesium. Both minerals are commonly under-consumed in the general population and become more so when total caloric intake drops. For more on magnesium: magnesium glycinate benefits.

Protein. This is the macronutrient deficiency with the most functional consequence during GLP-1 therapy. Reduced appetite means reduced protein intake, which combined with caloric deficit accelerates lean muscle loss. Stanford Medicine's GLP-1 guide recommends 100–140 grams of protein daily for a 200-pound person on GLP-1 therapy.

Biotin. Hair loss (telogen effluvium) during GLP-1 therapy is linked partly to rapid weight loss and partly to nutritional deficits including biotin, zinc, and iron. Supplementation may help mitigate this, though evidence is indirect.

A targeted nutritional formula designed for GLP-1 users addresses these gaps without requiring you to track each nutrient individually. For our formulation and the rationale behind each ingredient: best supplements for GLP-1 users.

How much do GLP-1 medications cost?

Cost has been the single largest barrier to GLP-1 access. Without insurance, brand-name GLP-1 list prices have historically topped $1,000 per month (KFF). Several developments in 2025–2026 have changed this picture.

Brand-name pricing. In November 2025, the U.S. government reached agreements with Novo Nordisk and Eli Lilly through the TrumpRx program, bringing the cash price of Ozempic, Wegovy, Mounjaro, and Zepbound to approximately $245 per month for eligible patients.

Compounded versions. Compounding pharmacies (503A and 503B facilities) have offered versions of semaglutide and tirzepatide at $200–$400 per month. That changed when the FDA began increasing enforcement against non-FDA-approved compounded GLP-1 products in February 2026, citing safety concerns. The long-term availability of compounded GLP-1 medications is uncertain.

Insurance coverage. Coverage varies dramatically. Most commercial insurers cover GLP-1 medications for type 2 diabetes but may require prior authorization. Coverage for weight management (Wegovy, Zepbound) is less consistent. Medicaid spending on GLP-1 drugs grew from approximately $1 billion in 2019 to $8.6 billion in 2024.

GLP-1 and exercise: what changes?

Resistance training becomes non-negotiable during GLP-1 therapy. In any caloric deficit, the body loses both fat and lean muscle mass. Without resistance training, a network meta-analysis of 22 RCTs found lean mass accounts for roughly 25% of total weight lost on GLP-1 drugs, with DXA substudies reporting a range of 26–40%.

Stanford Medicine's GLP-1 guide explicitly recommends pairing GLP-1 therapy with resistance training and adequate protein intake (1.0–1.6 g per kg daily) as the two most evidence-backed strategies for preserving lean mass during pharmacological weight loss.

This combination , medication for appetite regulation, training for body composition, protein for muscle preservation , is the current standard of care in obesity medicine. Cardiovascular exercise remains beneficial for heart health, metabolic fitness, and mental health, but it does not prevent muscle loss. Prioritize lifting, bodyweight exercises, or resistance bands alongside whatever cardio you enjoy.

What is the difference between GLP-1 supplements and GLP-1 medications?

This distinction matters because it is the single biggest source of consumer confusion in this space. GLP-1 medications (Ozempic, Wegovy, Mounjaro, Zepbound) are FDA-approved prescription drugs that contain synthetic GLP-1 receptor agonists. They produce clinically significant weight loss (7–24% of body weight; Stanford Medicine). GLP-1 supplements are dietary supplements that do not contain semaglutide, tirzepatide, or any GLP-1 receptor agonist. They cannot replicate the clinical effect of GLP-1 medications.

What well-formulated GLP-1 support formulas can do is address the nutritional consequences of being on a GLP-1 medication: replenishing B12, iron, zinc, and magnesium; supporting digestive comfort with probiotics and digestive enzymes; and providing ingredients like ginger that have evidence for reducing nausea. The honest framing: GLP-1 medications are the treatment.

These formulas are nutritional support for people already on the treatment. They serve different roles and should not be confused with each other. The same confusion drives the market for GLP-1 patches sold as needle-free alternatives, which contain no prescription medication at all.

What does the safety data say so far?

The long-term safety profile is still being established. Cardiovascular data is encouraging: the SELECT trial showed a 20% reduction in major adverse cardiovascular events. Thyroid cancer risk remains theoretical based on animal studies, with no signal in human data. Pancreatitis incidence is low (~0.2% in trials).

For detailed analysis of every long-term risk, including cancer, pancreatitis, gastroparesis, and muscle loss, see GLP-1 Side Effects: Long-Term Risks.

Watch: a Stanford endocrinologist on GLP-1 weight-loss drugs

Stanford Medicine endocrinologist Sun Kim, MD, walks through how GLP-1 medications actually work, who they are for, and what the clinical evidence says about long-term use. Covers the difference between semaglutide and tirzepatide, realistic expectations for weight loss, and how to evaluate whether a GLP-1 medication is appropriate for you.

Why YourHealthier

We do not prescribe GLP-1 medications , that is your physician's role. What we noticed is that millions of people starting these drugs have nutritional questions the prescribing visit does not always cover: what to eat when you are not hungry, which vitamins to supplement when your intake drops, how to manage the nausea and GI discomfort. Those are supplement and nutrition questions, and they are exactly what we do.

Our was formulated with the specific nutritional gaps GLP-1 therapy creates , B12, iron, zinc, digestive enzymes, probiotics, ginger for nausea support , reviewed by our medical team and third-party tested at accredited laboratories. It is not a replacement for your medication. It is designed to help you tolerate it better and maintain nutritional adequacy while your appetite is suppressed.

Frequently asked questions

Related reading

• Best Supplements for GLP-1 / Ozempic Users
• Berberine: Benefits for Blood Sugar and Metabolism
• Magnesium Glycinate: 7 Benefits Over Other Forms
• Magnesium Glycinate Dosage: How Much by Goal
• Best Time to Take Magnesium Glycinate
• 9 Magnesium Deficiency Symptoms
• Best Electrolyte Powder: LMNT vs Alternatives
• What Are Electrolytes?
• Does Creatine Make You Gain Weight?
• Best Supplement Stacks

Authoritative Resources

For independent, government-reviewed information on GLP-1 medications, consult these primary sources:

• FDA , Medications Containing Semaglutide
• NIH , GLP-1 Receptor Agonists (StatPearls)
• CDC , Adult Obesity Facts

Testing & Transparency Methodology

Every YourHealthier product referenced here is manufactured in an FDA-registered facility and undergoes independent third-party testing at accredited laboratories (ISO/IEC 17025, A2LA, or Eurofins, depending on the product). Each batch is screened for heavy metals (lead, cadmium, mercury, arsenic) and microbial contamination (total plate count, yeast, mold, E. coli, Salmonella) using validated USP, AOAC, and ICP-MS methods.

Batch-specific certificates of analysis are published at yourhealthier.com/pages/lab-results and updated with each new manufacturing run. All testing complies with current Good Manufacturing Practices (21 CFR Part 111). This article is written for general educational purposes and is not medical advice; it has not been evaluated by the FDA and is not intended to diagnose, treat, cure, or prevent any disease.

References

Related Reading

• GLP-1 side effects: causes, timeline, and how to manage them
• GLP-1 weight loss: how it works and what to expect
• Natural GLP-1: foods and compounds that support GLP-1
• Best GLP-1 supplements (2026): companion vitamins
• GLP-1 and alcohol: interactions, cravings, and safety

Disclosure: YourHealthier sells a GLP-1 Companion Supplement formulated to support nutritional needs during GLP-1 therapy. We do not sell semaglutide, tirzepatide, or any prescription GLP-1 medication. All health claims are based on published peer-reviewed research cited above. We earn revenue from product sales linked in this article. See our Editorial Policy.

Dietary supplements do not replace GLP-1 medications and are not a substitute for a prescriber’s care. Never start, stop, or change a prescription based on information in this article. This statement has not been evaluated by the Food and Drug Administration. This product is not intended to diagnose, treat, cure, or prevent any disease. This article is for informational purposes only and is not intended as medical advice.

GLP-1 at a Glance

Metric	Value
Weight loss (clinical trials)	7-24% of body weight
Tirzepatide (Zepbound)	~20-22.5%
Semaglutide (Wegovy)	~15%
Nausea (most common SE)	20-44% of users
Regain after stopping	~2 lb/month
MACE reduction	14-20%

Chart: GLP-1 at a Glance. Data: Weight loss in clinical trials: 7-24% of body weight; Tirzepatide (Zepbound): ~20-22.5%; Semaglutide (Wegovy): ~15%; Nausea, the most common side effect: 20-44% of users; Weight regain after stopping: ~2 lb per month; Major adverse cardiovascular event reduction: 14-20%. yourhealthier.com